Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $86.80.
Several analysts recently commented on GPCR shares. Morgan Stanley started coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, JMP Securities dropped their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research note on Friday, August 9th.
Get Our Latest Report on Structure Therapeutics
Structure Therapeutics Price Performance
Shares of NASDAQ:GPCR traded down $0.07 during trading on Wednesday, hitting $32.71. 489,266 shares of the company were exchanged, compared to its average volume of 782,517. The stock has a market capitalization of $1.87 billion, a P/E ratio of -44.09 and a beta of -3.23. Structure Therapeutics has a 12-month low of $26.61 and a 12-month high of $66.38. The firm's 50 day moving average price is $39.28 and its 200-day moving average price is $39.70.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sandia Investment Management LP purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth about $39,000. Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares during the period. Quarry LP purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after acquiring an additional 1,420 shares during the period. Finally, Dearborn Partners LLC purchased a new position in shares of Structure Therapeutics during the 3rd quarter worth about $202,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.
Structure Therapeutics Company Profile
(
Get Free ReportStructure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
